Total Payments
$38,591
2024 Payments
$7,285
Companies
9
Transactions
49
Medicare Patients
562
Medicare Billing
$51,885
Payment Breakdown by Category
Other$14,196 (36.8%)
Consulting$8,499 (22.0%)
Research$8,398 (21.8%)
Travel$4,358 (11.3%)
Education$2,500 (6.5%)
Food & Beverage$639.56 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,196 | 3 | 36.8% |
| Consulting Fee | $8,499 | 7 | 22.0% |
| Unspecified | $8,398 | 6 | 21.8% |
| Travel and Lodging | $4,358 | 19 | 11.3% |
| Education | $2,500 | 1 | 6.5% |
| Food and Beverage | $639.56 | 13 | 1.7% |
Payments by Type
General
$30,193
43 transactions
Research
$8,398
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $10,764 | 10 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $8,398 | 6 | $0 (2022) |
| Kyowa Kirin, Inc. | $7,667 | 14 | $0 (2023) |
| Ipsen Biopharmaceuticals, Inc | $7,281 | 7 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $3,250 | 4 | $0 (2024) |
| Celltrion, Inc. | $850.00 | 1 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $209.70 | 3 | $0 (2019) |
| Celgene Corporation | $86.00 | 2 | $0 (2018) |
| GENZYME CORPORATION | $86.00 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,285 | 10 | Ipsen Biopharmaceuticals, Inc ($4,781) |
| 2023 | $13,973 | 16 | Kyowa Kirin, Inc. ($7,667) |
| 2022 | $8,398 | 6 | Regeneron Pharmaceuticals, Inc. ($8,398) |
| 2021 | $3,250 | 2 | Ipsen Biopharmaceuticals, Inc ($2,500) |
| 2019 | $63.00 | 1 | E.R. Squibb & Sons, L.L.C. ($63.00) |
| 2018 | $172.00 | 4 | Celgene Corporation ($86.00) |
| 2017 | $5,451 | 10 | Amgen Inc. ($5,304) |
All Payment Transactions
49 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Celltrion, Inc. | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 11/15/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 08/21/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $54.03 | General |
| 04/19/2024 | Ipsen Biopharmaceuticals, Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,700.00 | General |
| 03/14/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 03/12/2024 | Ipsen Biopharmaceuticals, Inc | — | Travel and Lodging | In-kind items and services | $855.72 | General |
| 03/12/2024 | Ipsen Biopharmaceuticals, Inc | — | Travel and Lodging | In-kind items and services | $762.31 | General |
| 03/12/2024 | Ipsen Biopharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $399.00 | General |
| 03/12/2024 | Ipsen Biopharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $35.26 | General |
| 03/12/2024 | Ipsen Biopharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $28.25 | General |
| 12/19/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,090.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 12/19/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | Cash or cash equivalent | $103.62 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 12/19/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | Cash or cash equivalent | $29.63 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 12/19/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | Cash or cash equivalent | $4.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/28/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $98.23 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/28/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $44.50 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/28/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $44.50 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/28/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $9.82 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/28/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $9.82 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/27/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $507.09 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/27/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $323.50 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/27/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $171.20 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/27/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $119.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/27/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $111.63 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 06/14/2023 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva | Regeneron Pharmaceuticals, Inc. | $8,398 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 197 | 206 | $78,284 | $20,500 |
| 2022 | 7 | 143 | 152 | $56,699 | $12,101 |
| 2021 | 8 | 163 | 185 | $19,293 | $14,516 |
| 2020 | 4 | 59 | 67 | $7,534 | $4,768 |
Total Patients
562
Total Services
610
Medicare Billing
$51,885
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 42 | 42 | $23,776 | $6,619 | 27.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 41 | 41 | $18,891 | $5,077 | 26.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 15 | $6,675 | $2,011 | 30.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 19 | 20 | $5,636 | $1,825 | 32.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 28 | 28 | $5,093 | $1,427 | 28.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 25 | 33 | $6,072 | $1,227 | 20.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 14 | 14 | $4,522 | $1,179 | 26.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 13 | $7,618 | $1,135 | 14.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 21 | 21 | $9,996 | $2,760 | 27.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 20 | 20 | $12,060 | $2,587 | 21.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 23 | 24 | $13,584 | $2,506 | 18.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 22 | 23 | $6,164 | $1,231 | 20.0% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 16 | 16 | $6,208 | $1,221 | 19.7% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 28 | 35 | $6,230 | $926.87 | 14.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 13 | $2,457 | $868.73 | 35.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 23 | 23 | $3,810 | $3,034 | 79.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 19 | 19 | $4,152 | $2,872 | 69.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 24 | 25 | $2,368 | $1,696 | 71.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 36 | 56 | $2,228 | $1,649 | 74.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 11 | 11 | $1,974 | $1,457 | 73.8% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 18 | 18 | $1,747 | $1,418 | 81.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 11 | 12 | $1,546 | $1,255 | 81.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 21 | 21 | $1,467 | $1,135 | 77.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 26 | 26 | $3,499 | $1,850 | 52.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 11 | 11 | $2,262 | $1,721 | 76.1% |
About Dr. Matthew Drake, MD
Dr. Matthew Drake, MD is a General Practice healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790871713.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Drake, MD has received a total of $38,591 in payments from pharmaceutical and medical device companies, with $7,285 received in 2024. These payments were reported across 49 transactions from 9 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($14,196).
As a Medicare-enrolled provider, Drake has provided services to 562 Medicare beneficiaries, totaling 610 services with total Medicare billing of $51,885. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty General Practice
- Other Specialties Diabetes & Metabolism
- Location Rochester, MN
- Active Since 10/05/2006
- Last Updated 01/30/2025
- Taxonomy Code 208D00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1790871713
Products in Payments
- Crysvita (Drug) $7,667
- Prolia (Biological) $5,406
- STRENSIQ (Biological) $900.00
- NO PRODUCT DISCUSSED (Drug) $86.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
General Practice Doctors in Rochester
Sarah Atkinson, Md, MD
General Practice — Payments: $1.4M
General Practice $1.4M
Steven Ytterberg, M.d, M.D
General Practice — Payments: $127,642
General Practice $127,642
Adrian Vella, M.d, M.D
General Practice — Payments: $53,347
General Practice $53,347
Yogish Kudva, Mbbs, MBBS
General Practice — Payments: $35,396
General Practice $35,396
Michael Jensen, M.d, M.D
General Practice — Payments: $34,497
General Practice $34,497
Dr. Frank Lamar, D.d.s, D.D.S
General Practice — Payments: $34,205
General Practice $34,205